Based on the Healius Limited stock forecast from 0 analysts, the average analyst target price for Healius Limited is not available over the next 12 months. Healius Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Healius Limited is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Healius Limited’s stock price was EUR 0.80. Healius Limited’s stock price has changed by -0.62% over the past week, +3.90% over the past month and -13.51% over the last year.
No recent analyst target price found for Healius Limited
No recent average analyst rating found for Healius Limited
Company Overview Healius Limited
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics, QML Pathology, TML Pathology, Abbott Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories, medical centers, patient collection centers, and community imaging centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia. Read Less
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. The company p...Read More
Frequently Asked Questions About Healius Limited (PGZ:F) Stock
Stock Target Advisor's fundamental analysis for Healius Limited's stock is Slightly Bearish.
Unfortunately we do not have enough data on PGZ:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PGZ:F's stock to indicate what its average analyst target is.
PGZ:F stock's Price/Earning ratio is 51.00.
Our analysis grades PGZ:F stock's Price / Earning ratio at F. This means that PGZ:F stock's Price/Earning ratio is above 76% of the stocks in the Diagnostics & Research sector in the F exchange.
Based on this PGZ:F may be a overvalued for its sector.
The last closing price of PGZ:F's stock was EUR 0.80.
The most recent market capitalization for PGZ:F is EUR 0.64B.
Unfortunately we do not have enough analyst data on PGZ:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Healius Limited's stock.
As per our most recent records Healius Limited has 4,329 Employees.
Healius Limited's registered address is 161 Castlereagh Street, Sydney, NSW, Australia, 2000.
You can get more information about it from Healius Limited's website at https://www.healius.com.au.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Healius Limited (PGZ:F) Stock
Stock Target Advisor's fundamental analysis for Healius Limited's stock is Slightly Bearish.
Unfortunately we do not have enough data on PGZ:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PGZ:F's stock to indicate what its average analyst target is.
PGZ:F stock's Price/Earning ratio is 51.00.
Our analysis grades PGZ:F stock's Price / Earning ratio at F. This means that PGZ:F stock's Price/Earning ratio is above 76% of the stocks in the Diagnostics & Research sector in the F exchange.
Based on this PGZ:F may be a overvalued for its sector.
The last closing price of PGZ:F's stock was EUR 0.80.
The most recent market capitalization for PGZ:F is EUR 0.64B.
Unfortunately we do not have enough analyst data on PGZ:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Healius Limited's stock.
As per our most recent records Healius Limited has 4,329 Employees.
Healius Limited's registered address is 161 Castlereagh Street, Sydney, NSW, Australia, 2000.
You can get more information about it from Healius Limited's website at https://www.healius.com.au.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PGZ:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
